Digital Biomarkers in Multiple Sclerosis

For incurable diseases, such as multiple sclerosis (MS), the prevention of progression and the preservation of quality of life play a crucial role over the entire therapy period. In MS, patients tend to become ill at a younger age and are so variable in terms of their disease course that there is no...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anja Dillenseger, Marie Luise Weidemann, Katrin Trentzsch, Hernan Inojosa, Rocco Haase, Dirk Schriefer, Isabel Voigt, Maria Scholz, Katja Akgün, Tjalf Ziemssen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple sclerosis digital biomarkers digital health technology eHealth precision medicine personalized therapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/1cb983341f014702947ab3c2da14a9c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1cb983341f014702947ab3c2da14a9c5
record_format	dspace
spelling	oai:doaj.org-article:1cb983341f014702947ab3c2da14a9c52021-11-25T16:58:53ZDigital Biomarkers in Multiple Sclerosis10.3390/brainsci111115192076-3425https://doaj.org/article/1cb983341f014702947ab3c2da14a9c52021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1519https://doaj.org/toc/2076-3425For incurable diseases, such as multiple sclerosis (MS), the prevention of progression and the preservation of quality of life play a crucial role over the entire therapy period. In MS, patients tend to become ill at a younger age and are so variable in terms of their disease course that there is no standard therapy. Therefore, it is necessary to enable a therapy that is as personalized as possible and to respond promptly to any changes, whether with noticeable symptoms or symptomless. Here, measurable parameters of biological processes can be used, which provide good information with regard to prognostic and diagnostic aspects, disease activity and response to therapy, so-called biomarkers Increasing digitalization and the availability of easy-to-use devices and technology also enable healthcare professionals to use a new class of digital biomarkers—digital health technologies—to explain, influence and/or predict health-related outcomes. The technology and devices from which these digital biomarkers stem are quite broad, and range from wearables that collect patients’ activity during digitalized functional tests (e.g., the Multiple Sclerosis Performance Test, dual-tasking performance and speech) to digitalized diagnostic procedures (e.g., optical coherence tomography) and software-supported magnetic resonance imaging evaluation. These technologies offer a timesaving way to collect valuable data on a regular basis over a long period of time, not only once or twice a year during patients’ routine visit at the clinic. Therefore, they lead to real-life data acquisition, closer patient monitoring and thus a patient dataset useful for precision medicine. Despite the great benefit of such increasing digitalization, for now, the path to implementing digital biomarkers is widely unknown or inconsistent. Challenges around validation, infrastructure, evidence generation, consistent data collection and analysis still persist. In this narrative review, we explore existing and future opportunities to capture clinical digital biomarkers in the care of people with MS, which may lead to a digital twin of the patient. To do this, we searched published papers for existing opportunities to capture clinical digital biomarkers for different functional systems in the context of MS, and also gathered perspectives on digital biomarkers under development or already existing as a research approach.Anja DillensegerMarie Luise WeidemannKatrin TrentzschHernan InojosaRocco HaaseDirk SchrieferIsabel VoigtMaria ScholzKatja AkgünTjalf ZiemssenMDPI AGarticlemultiple sclerosisdigital biomarkersdigital health technologyeHealthprecision medicinepersonalized therapyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1519, p 1519 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple sclerosis digital biomarkers digital health technology eHealth precision medicine personalized therapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	multiple sclerosis digital biomarkers digital health technology eHealth precision medicine personalized therapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Anja Dillenseger Marie Luise Weidemann Katrin Trentzsch Hernan Inojosa Rocco Haase Dirk Schriefer Isabel Voigt Maria Scholz Katja Akgün Tjalf Ziemssen Digital Biomarkers in Multiple Sclerosis
description	For incurable diseases, such as multiple sclerosis (MS), the prevention of progression and the preservation of quality of life play a crucial role over the entire therapy period. In MS, patients tend to become ill at a younger age and are so variable in terms of their disease course that there is no standard therapy. Therefore, it is necessary to enable a therapy that is as personalized as possible and to respond promptly to any changes, whether with noticeable symptoms or symptomless. Here, measurable parameters of biological processes can be used, which provide good information with regard to prognostic and diagnostic aspects, disease activity and response to therapy, so-called biomarkers Increasing digitalization and the availability of easy-to-use devices and technology also enable healthcare professionals to use a new class of digital biomarkers—digital health technologies—to explain, influence and/or predict health-related outcomes. The technology and devices from which these digital biomarkers stem are quite broad, and range from wearables that collect patients’ activity during digitalized functional tests (e.g., the Multiple Sclerosis Performance Test, dual-tasking performance and speech) to digitalized diagnostic procedures (e.g., optical coherence tomography) and software-supported magnetic resonance imaging evaluation. These technologies offer a timesaving way to collect valuable data on a regular basis over a long period of time, not only once or twice a year during patients’ routine visit at the clinic. Therefore, they lead to real-life data acquisition, closer patient monitoring and thus a patient dataset useful for precision medicine. Despite the great benefit of such increasing digitalization, for now, the path to implementing digital biomarkers is widely unknown or inconsistent. Challenges around validation, infrastructure, evidence generation, consistent data collection and analysis still persist. In this narrative review, we explore existing and future opportunities to capture clinical digital biomarkers in the care of people with MS, which may lead to a digital twin of the patient. To do this, we searched published papers for existing opportunities to capture clinical digital biomarkers for different functional systems in the context of MS, and also gathered perspectives on digital biomarkers under development or already existing as a research approach.
format	article
author	Anja Dillenseger Marie Luise Weidemann Katrin Trentzsch Hernan Inojosa Rocco Haase Dirk Schriefer Isabel Voigt Maria Scholz Katja Akgün Tjalf Ziemssen
author_facet	Anja Dillenseger Marie Luise Weidemann Katrin Trentzsch Hernan Inojosa Rocco Haase Dirk Schriefer Isabel Voigt Maria Scholz Katja Akgün Tjalf Ziemssen
author_sort	Anja Dillenseger
title	Digital Biomarkers in Multiple Sclerosis
title_short	Digital Biomarkers in Multiple Sclerosis
title_full	Digital Biomarkers in Multiple Sclerosis
title_fullStr	Digital Biomarkers in Multiple Sclerosis
title_full_unstemmed	Digital Biomarkers in Multiple Sclerosis
title_sort	digital biomarkers in multiple sclerosis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1cb983341f014702947ab3c2da14a9c5
work_keys_str_mv	AT anjadillenseger digitalbiomarkersinmultiplesclerosis AT marieluiseweidemann digitalbiomarkersinmultiplesclerosis AT katrintrentzsch digitalbiomarkersinmultiplesclerosis AT hernaninojosa digitalbiomarkersinmultiplesclerosis AT roccohaase digitalbiomarkersinmultiplesclerosis AT dirkschriefer digitalbiomarkersinmultiplesclerosis AT isabelvoigt digitalbiomarkersinmultiplesclerosis AT mariascholz digitalbiomarkersinmultiplesclerosis AT katjaakgun digitalbiomarkersinmultiplesclerosis AT tjalfziemssen digitalbiomarkersinmultiplesclerosis
_version_	1718412822765895680

Digital Biomarkers in Multiple Sclerosis

Ejemplares similares